We aim to present an easily understandable version of the latest medical research on MDS
You will be able to read up here the latest research projects and use this information to discuss with your consultants or nurses.
Evidence shows that when you are actively involved in your own care, treatment and support, it can improve your outcomes and experience of the disease.
All the articles listed in this page have been properly vetted for scientific accuracy.
Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Print this article In this article Dr Chris Dalley, Consultant Haematologist University Hospital Southampton (NHS Foundation Trust), looks at the use of conventional and new Erythropoiesis Stimulating Agents (ESAs) in the treatment of MDS. What are Erythropoiesis Stimulating […]Read full story
Sophie Wintrich, Chief Executive of the MDS UK Patient Support Group, interviewed Prof. David Bowen – Consultant Haematologist at St James University Hospital, Leeds. Watch the video and read the excerpts below. "We've always practiced personalised medicine" “Personalised medicine means that you sit with an individual in front of you and you consider them as […]Read full story
Are Vidaza and Azacitidine the same drug? Why does it have two names? Vidaza and Azacitidine are the same drug Azacitidine is the official generic and non-proprietary name given to the drug active ingredient while Vidaza is its trade name. The drug is widely available in the UK for the treatment of MDS since its […]Read full story
Car-t cell therapy aims to boost the immune system to attack tumor cells Cell therapies, sometimes called “living therapies”, are an especially promising and rapidly growing area of cancer research. One approach that’s been pioneered by Memorial Sloan Kettering researchers, led by investigator Michel Sadelain, is called CAR-T cell immunotherapy. This type of targeted immunotherapy […]Read full story
When is a blood transfusion considered? How low should the cell count be? When the blood lacks enough healthy red blood cells or haemoglobin, anemia symptoms develop, typically fatigue, shortness of breath, weight loss, paler than normal skin, etc and a blood transfusion is considered. There is no set haemoglobin level at which a blood […]Read full story
More than 70 participants representing medical specialists and nurses caring for MDS patients, MDS patient advocates, medical researchers and data managers, healthcare authorities, regulators, HTA experts and industry representatives gathered for the first MDS-RIGHT multi-stakeholder meeting on the 3 May 2017 in Valencia, Spain – in conjunction with the biannual MDS 2017 International Symposium. This […]Read full story
A new project was trialled for more than two years by nurses from home-care units in Spain: ‘Azacitidine (Vidaza) administration at home’. Now it has been rolled out to include most of the hospitals in Spain administering Azacitidine. It was initially undertaken by nurses, not necessarily haematology nurses, who would visit patients at home usually by taxi […]Read full story
The following videos come from the annual UK MDS Forum Education Day 2016, which took place in London on 11th November 2016. The day is targeted at all haematologists in the UK and Ireland who deal with MDS patients. Its aim is to provide information and updates on the most advanced scientific and clinical research […]Read full story
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Fabio Efficace discusses the importance of quality of life as a treatment goal in myelodysplastic syndromes (MDS) Dr. F. Efficace discusses importance of Quality of Life as Treatment Goal in MDS When latest genetic analysis and therapeutic strategies are incorporated into MDS […]Read full story
Researchers designed an antibody that recognises and destroys CD99-covered leukemia cells while sparing normal blood stem cells This is a microscopic image of a leukemia cancer stem cell (Credit: Montreh Tavakkoli) with normal DNA coloured in blue. CD99, those green-coloured spots, is a protein-sugar molecule, which occurs more frequently than normal on stem cells responsible […]Read full story